Evidence map›Paper›PMID 40533493›Full record

ArticleCommunications medicine2025

Clinical manifestations of sickle cell disease in Africa and its association with foetal haemoglobin parameters.

Evans Xorse Amuzu, Florence Urio, Elliot Eli Dogbe, Peter Ponsian, Suraj Yawnumah Abubakar, Chinedu Okeke, Olasinbo Olumuyiwa Balogun, Petronilla Jean Ozumba, Alex Osei-Akoto, Vivian Paintsil and 6 more

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Evans Xorse AmuzuKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana. evansxamuzu@gmail.com.ORCID http://orcid.org/0000-0001-5977-5706
Florence UrioDepartment of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
Elliot Eli DogbeKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana.
Peter PonsianDepartment of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania.
Suraj Yawnumah AbubakarKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana.
Chinedu OkekeCentre of Excellence for Sickle Cell Disease Research & Training, University of Abuja (CESRTA), Abuja, Federal Capital Territory, Abuja, Nigeria.
Olasinbo Olumuyiwa BalogunInstitute of Human Virology Nigeria, Abuja, Nigeria.ORCID http://orcid.org/0000-0001-9411-2983
Petronilla Jean OzumbaInstitute of Human Virology Nigeria, Abuja, Nigeria.
Alex Osei-AkotoKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana.
Vivian PaintsilKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana.ORCID http://orcid.org/0000-0002-8965-0549
Obiageli NnoduCentre of Excellence for Sickle Cell Disease Research & Training, University of Abuja (CESRTA), Abuja, Federal Capital Territory, Abuja, Nigeria.
Emmanuel BalandyaSickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Julie MakaniSickle Cell Programme, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Madu AnazoezeDepartment of Haematology and Immunology, University of Nigeria, Nsukka, Enugu State, Nigeria.
Daniel AnsongKumasi Centre for Sickle Cell Disease- Komfo Anokye Teaching Hospital (KCSCD-KATH), Kumasi, Ghana.
Siana NkyaDepartment of Biochemistry and Molecular Biology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania. snkyamtatiro@gmail.com.

Funding

International Centre for Genetic Engineering and Biotechnology (ICGEB) CRP/TZA19-01
6 · The paper itself

Abstract

backgroundPrevalence of sickle cell disease (SCD) across African countries ranges between 1-3% and contributes up to 7-16% of under-five mortality. In order to bridge the gap in management and cognate research, the SickleInAfrica consortium was established in 2017 to facilitate collaboration among African nations in order to establish regionally relevant healthcare standards for SCD patients. This work utilised the SickleInAfrica platform to study the levels of HbF and F cells and their relationship with sickle cell disease clinical manifestations in Ghana, Nigeria and Tanzania.

methodsThis study enrolled 290 individuals with SCD aged five years and above who were confirmed to be at steady state and were hydroxyurea naïve. Clinical history was obtained using an interviewer-administered questionnaire. Haematological parameters were determined by an automated haematology analyser, while quantification of HbF and F cells was implemented by high-performance liquid chromatography and flow cytometry, respectively. Age-adjusted logistic regression was employed to assess the association of HbF with the clinical manifestations.

resultsThe most reported complication of SCD, requiring management in a hospital setting is pain crises, ranging from 66-96% with the highest in Tanzania and lowest in Ghana. HbF and F cell parameters show significant association with transfusion rates, frequency of painful crises and episodes of febrile illness.

conclusionThis work highlights important differences and similarities across SCD populations in the three countries. This is important especially in development of interventions in the light of personalised medicine.

Identifiers

PMID40533493
PMCPMC12177083

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.